Apnimed priced an upsized $192 million IPO as it advances Oxnimbi (AD109), its combination oral therapy for obstructive sleep apnea, toward a targeted FDA decision in early 2027. The company’s Phase 3 program included a study of 660 patients in which the regimen reduced nightly breath-stopping events versus placebo, reinforcing the launch case ahead of the regulatory timeline.